Responses
Clinical and epidemiological research
Extended report
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16
Compose a Response to This Article
Other responses
No responses have been published for this article.